同和药业
(300636)
| 流通市值：28.68亿 | | | 总市值：33.17亿 |
| 流通股本：3.64亿 | | | 总股本：4.22亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 569,933,408.38 | 382,051,594.68 | 206,454,983.02 | 722,138,705.43 |
| 营业收入 | 569,933,408.38 | 382,051,594.68 | 206,454,983.02 | 722,138,705.43 |
| 二、营业总成本 | 455,177,777.45 | 295,168,592.6 | 150,662,133.88 | 599,899,694.96 |
| 营业成本 | 378,090,930.9 | 250,138,319.2 | 130,754,859.21 | 481,658,031.74 |
| 税金及附加 | 5,380,972.73 | 3,391,661.69 | 859,073.9 | 3,663,137.67 |
| 销售费用 | 18,674,206.69 | 12,660,645.86 | 5,925,788.93 | 26,255,096.1 |
| 管理费用 | 26,858,732.18 | 17,444,427.45 | 8,397,949.83 | 34,570,543.15 |
| 研发费用 | 39,204,527.63 | 22,181,806.93 | 10,292,403.05 | 63,151,225.15 |
| 财务费用 | -13,031,592.68 | -10,648,268.53 | -5,567,941.04 | -9,398,338.85 |
| 其中:利息费用 | 13,176,657.04 | 8,911,778.28 | 4,062,134.72 | 9,895,391.93 |
| 其中:利息收入 | 23,114,601.72 | 16,216,862.52 | 9,013,826.29 | 17,010,576.73 |
| 加:投资收益 | 606,704.78 | -45,884.66 | - | 567,878.95 |
| 资产处置收益 | -706,142.86 | -706,142.86 | 0 | -1,320,772.82 |
| 资产减值损失(新) | -12,375,041.28 | -11,914,375.02 | -7,920,742.47 | -19,143,082.69 |
| 信用减值损失(新) | -1,860,939.34 | -1,988,189.34 | -2,525,755.02 | 107,338.4 |
| 其他收益 | 5,590,954.46 | 4,979,556.11 | 3,685,602.25 | 9,781,885.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 106,011,166.69 | 77,207,966.31 | 49,031,953.9 | 112,232,257.94 |
| 加:营业外收入 | 1.36 | - | 0 | 354,079.9 |
| 减:营业外支出 | 512,910.72 | 66,750 | 66,750 | 85,990 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 105,498,257.33 | 77,141,216.31 | 48,965,203.9 | 112,500,347.84 |
| 减:所得税费用 | 9,761,795.73 | 7,589,193.91 | 5,402,452.76 | 6,517,090.69 |
| 六、净利润 | 95,736,461.6 | 69,552,022.4 | 43,562,751.14 | 105,983,257.15 |
| 持续经营净利润 | 95,736,461.6 | 69,552,022.4 | - | 105,983,257.15 |
| 归属于母公司股东的净利润 | 95,736,461.6 | 69,552,022.4 | 43,562,751.14 | 105,983,257.15 |
| (一)基本每股收益 | 0.23 | 0.17 | 0.1 | 0.28 |
| (二)稀释每股收益 | 0.23 | 0.17 | 0.1 | 0.28 |
| 九、综合收益总额 | 95,736,461.6 | 69,552,022.4 | 43,562,751.14 | 105,983,257.15 |
| 归属于母公司股东的综合收益总额 | 95,736,461.6 | 69,552,022.4 | 43,562,751.14 | 105,983,257.15 |
| 公告日期 | 2024-10-24 | 2024-08-29 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |